New drug cocktail aims to crush High-Risk myeloma
NCT ID NCT03104842
First seen May 19, 2026 · Last updated May 20, 2026 · Updated 1 time
Summary
This study tests a combination of four drugs (isatuximab, carfilzomib, lenalidomide, and dexamethasone) in 246 people newly diagnosed with high-risk multiple myeloma. The goal is to see if this treatment can make cancer undetectable in the bone marrow. Participants receive the drugs in three phases: induction, consolidation, and long-term maintenance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asklepios Altona
Hamburg, Germany
-
Campus Benjamin Franklin Charite Berlin
Berlin, Germany
-
Johanniter-Krankenhaus Bonn
Bonn, 53113, Germany
-
Kliniken Maria Hilf GmbH, Klinik für Hämatologie, Onkologie und Gastroenterologie
Mönchengladbach, 41063, Germany
-
Klinikum Osnabrück
Osnabrück, Germany
-
Philipps-Universität Marburg
Marburg, 35032, Germany
-
St. Antonius Hospital
Eschweiler, Germany
-
Städt. Kliniken Bielefeld Klinikum Mitte
Bielefeld, Germany
-
Uniklinik Köln
Cologne, Germany
-
Uniklinikum Chemnitz
Chemnitz, Germany
-
University Hospital Hamburg Eppendorf
Hamburg, Germany
-
University Hospital Heidelberg
Heidelberg, Germany
-
Universitätsklinikum Essen
Essen, Germany
-
Universitätsklinikum Tuebingen
Tübingen, Germany
-
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
Mainz, D-55131, Germany
-
Vivantes Am Urban
Berlin, 10967, Germany
-
Vivantes Klinikum Neukölln
Berlin, Germany
Conditions
Explore the condition pages connected to this study.